Elmiron (pentosan polysulfate sodium) was approved by the U.S. Food & Drug Administration (FDA) for the consumer market on September 26, 1996 for the treatment of interstitial cystitis (IC). A little over 23 years later in October 2019, the American Academy of Ophthalmology shared results linking maculopathy, a vision-threatening eye condition, to prolonged use of this bladder drug.
As more and more patients come forward with signs of irreversible vision loss, lawsuits are forming against the drugmaker, Janssen Pharmaceuticals. At Mike Brandner Injury Attorney, we empathize with those who have potentially lost their vision after taking this bladder medication.
Please contact us today for a free no-obligation case evaluation if you or a loved one took this prescription drug for at least one year and now suffer eye damage and/or vision loss.
The drugmaker may be obligated to provide compensation for your injuries and other damages to include medical bills, lost wages, loss of enjoyment of life, mental anguish, emotional distress, and other expenses associated with your pain and suffering.
What Is Interstitial Cystitis?
Interstitial cystitis (IC) is a chronic health condition that increases urinary frequency and urgency, bladder pain and pressure, as well as overall pelvic pain in both women and men. Symptoms of this painful bladder syndrome range from mild to severe and can come and go, which can make it difficult to diagnose and treat.
How Does Elmiron Work?
Elmiron is an oral capsule that is usually prescribed to IC patients in dosage amounts of 100mg to be taken three times a day.
Elmiron is thought to work by acting as a synthetic layer that attaches to the bladder wall, thus protecting the bladder from irritating substances. In turn, the patient taking Elmiron may feel a decrease in bladder pain and pressure.
Even though patients received some warnings of potential side effects after taking Elmiron, the drug packaging does not include anything about a risk of maculopathy or blindness.
Patients who have filed Elmiron lawsuits allege that Janssen Pharmaceuticals knew or should have known that pentosan polysulfate sodium caused maculopathy and neglected to include proper warning on packaging.
Janssen is further alleged of putting profit before patient care as Elmiron:
- Is the only FDA approved drug approved to treat interstitial cystitis.
- Has an expired patent with a lack of substitute drugs, forcing patients to pay thousands of dollars out-of-pocket for the medication.
- Profits only increase as the market for interstitial cystitis treatments continues to grow.
What Are the Symptoms of Maculopathy?
Patients who have taken Elmiron for a prolonged amount of time have contacted their doctor after noticing these vision problems:
- Dimming of vision
- Blurred vision
- Difficulty seeing objects up close
- Find it more difficult adjusting to the dark
- Noticing a blindspot in their field of vision
If you or a loved one has taken Elmiron and now show signs of any of the above symptoms, consult with your medical provider immediately. Doing so will help determine the cause of your decrease in vision. Should it be found that you have developed maculopathy, then contacting a lawyer is the best way to find out whether or not you have an Elmiron vision loss case.
Do You Have an Elmiron Vision Loss Case?
Mike Brandner Injury Attorneys encourages anyone who has been diagnosed with an eye disorder or vision problems after taking prescription Elmiron for over a year to contact our firm using the form on this page. You can also call us directly at 504-345-1111, or chat with a live representative online.
Specific eye condition injury claims we are currently evaluating include:
- Pigmentary maculopathy
- Degenerative maculopathy/macular degeneration
- Macular retinopathy
- Macular/pattern dystrophy
- Retinal pigment epithelium atrophy resulting in scotomas
- Unilateral or bilateral blindness
Don’t wait! Reach out to our Elmiron injury lawyers immediately to find out your legal options.Your injuries and subsequent damages may entitle you to substantial compensation.